Use of High-Dose Cyproterone Acetate and Risk of Intracranial Meningioma in Women: Cohort Study

    February 2021 in “ BMJ ”
    Alain Weill, P. Christine Nguyen, Moujahed Labidi … Joël Coste
    Studysummary This study found a strong dose-related increase in the risk of intracranial meningiomas associated with high doses of cyproterone acetate, with some reduction in risk after stopping the treatment.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on bmj.com →
    Discuss this study in the Community →

    Research cited in this study 1

    1. Risk of Meningioma Among Users of High Doses of Cyproterone Acetate Compared With the General Population: Evidence From a Population-Based Cohort Study British Journal of Clinical Pharmacology · 2011

    Related research 1

    1. Use of High-Dose Cyproterone Acetate and Risk of Intracranial Meningioma in Women: Cohort Study BMJ · 2021